Globally, development the arena of proteomics and nanotechnology, rising incidences of chronic and autoimmune diseases, rise in the awareness among people regarding protein drugs, increasing focus on research and development process, development in drug delivery system, and advantages of protein based drugs such as, high specificity, enhanced efficacy, affinity, solubility, and low incidences of toxicity are the prime growth drivers of global protein drugs market.
In addition, increase in adoption of protein drugs in emerging economies such as China, India and others, will create new opportunities for global protein drugs market. However, higher cost of the research and development, and complex government approval processes are the key restraints for global protein drugs market.
Geographically North America dominated global protein drugs market, with approximately half of the market in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing population chronic and autoimmune diseases patient in developing nations such as China, and India in this region. Among all the types, antibody segment has the highest market share in global protein drugs market due to higher prevalence of cancer patients.
- Eli Lilly
- Abbott Laboratories
- UCB Group
- Schering-Plough Corporation
- Genentech Inc.
- Johnson & Johnson
- Bristol-Myers Squibb
- Novo Nordisk
- Biogen Idec
Key Topics Covered:
1. Protein Drugs Market - Market Overview
2. Executive Summary
3. Market Landscape
4. Protein Drugs Market- Market Forces
5. Protein Drugs Market- Strategic Analysis
6. Protein Drugs Market, By Type
7. Protein Drugs Market, By Geography
8. Protein Drugs - Market Entropy
9. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/5qsz8z/protein_drugs